Novavax to Participate in Upcoming Investor Conferences
Novavax, Inc. (Nasdaq: NVAX), a prominent player in the development of innovative protein-based vaccines, has recently announced its involvement in two important investor conferences this month. The company is well-known for its unique Matrix-M™ adjuvant, which enhances the immune response to vaccines.
H.C. Wainwright 26th Annual Global Investment Conference
As part of its outreach strategy, Novavax will take part in the H.C. Wainwright 26th Annual Global Investment Conference. This event is scheduled for Monday, September 9, 2024, where the company will host a fireside chat from 3:30 PM to 4:00 PM Eastern Time. Vernon Bernardino, Managing Director and Senior Healthcare Analyst, will moderate the discussion. Notable participants from Novavax include Jim Kelly, Executive Vice President, Chief Financial Officer, and Treasurer, along with Robert Walker, MD, Senior Vice President and Chief Medical Officer.
Conference Insights
The fireside chat will provide investors with valuable insights into Novavax's strategies and upcoming initiatives. This session will serve as a platform to discuss the company's ongoing efforts to advance vaccine development technologies.
Baird 2024 Global Healthcare Conference
The second major event that Novavax will attend is the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024. During this conference, the company will present from 3:10 PM to 3:40 PM ET, highlighting its innovative vaccine pipeline and research initiatives. This event will also take place in New York City, offering enhanced networking opportunities for industry leaders and investors.
Commitment to Healthcare Solutions
At both conferences, Novavax will reaffirm its dedication to developing impactful healthcare solutions. The presence of top executives underscores the company's commitment to sharing its vision and progress with stakeholders.
Access to Conference Replays
A replay of both the fireside chat and the presentation will be available on the Events and Presentations page of Novavax's website. This ensures that those unable to attend can still access the discussions for 30 days following the conferences.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is committed to the discovery, development, and commercialization of innovative vaccines aimed at protecting against serious infectious diseases. The company employs a distinctive vaccine platform that integrates recombinant protein technologies and advanced nanoparticle solutions, along with its proprietary Matrix-M adjuvant. Novavax has a broad portfolio, which includes its COVID-19 vaccine and ongoing candidates targeting both COVID-19-Influenza combinations and standalone influenza therapies. Importantly, Novavax’s Matrix-M adjuvant plays a crucial role in the malaria vaccine developed by the University of Oxford and the Serum Institute of India.
Contact Information
Investors:
Erika Schultz
240-268-2022
[email protected]
Media:
Giovanna Chandler
202-709-5563
[email protected]
Frequently Asked Questions
What is Novavax's primary focus in the healthcare sector?
Novavax focuses on developing innovative vaccines to combat serious infectious diseases through its unique protein-based technology.
When is Novavax participating in investor conferences?
Novavax is participating in two investor conferences on September 9 and 10, 2024.
Who are the key participants from Novavax at the conferences?
Key participants include Jim Kelly, Executive Vice President and CFO, and Robert Walker, MD, Senior Vice President and CMO.
What platform does Novavax utilize for its vaccine development?
Novavax employs a recombinant protein approach combined with advanced nanoparticle technology and the Matrix-M adjuvant.
Where can I find the replay of the Novavax conference presentations?
The replay will be available on Novavax's Events and Presentations page for 30 days post-conference.
